Receipt date: 03/30/2007

PTO/SB/08a (08-03)

Approved for use through 07731206. OMB 08510031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 10/551.847 Application Number MAR 3 0 200 INFORMATION DISCLOSURE Filing Date June 23, 2006 STATEMENT BY APPLICANT HAIXIANG, LIN First Named Inventor Art Unit Unassigned Examiner Name Unassigned (use as many sheets as necessary) of Attorney Docket Number NBMP-001 Sheet

U.S. PATENT DOCUMENTS					
Examiner Initials'	Cite No.1	Document Number Number-Kind Code ¹ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US- 3,952,097	04-20-1976	Levy	
		US- 4,024,241	05-17-1977	Levy	
		US- 4,140,761	02-20-1979	Gerin et al.	
		US- 4,349,538	09-14-1982	Levy	
		US- 4,389,395	06-21-1983	Lerner et al.	
		US- 4,954,298	09-04-1990	Yamamoto et al.	
		US- 6,468,558	10-22-2002	Wong	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials'	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁴ (# known)	Publication Date -MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
•		JP 1186818	07-26-1989	YAMASA SHOYU KK; TOA EIYO LTD		
		JP 57002220	01-07-1982	TORAY INDUSTRIES		
		WO 2005/014038	02-17-2005	THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY		
		EP 0025766A3	03-25-1981	MERCK & CO.		
		EP 0025766A2	03-25-1981	MERCK & CO.		

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	T²			
		HOUSTON et al. "Modified Polyriboinosinic-Polyribocytidylic Acid, an Immunological Adjuvant," Infection and Immunity, American Society for Microbiology, July 1976, Vol. 14(1) p. 318-319.				
		KENDE et al. "Enhanced Therapeutic Efficacy of Poly(ICLC) and Ribavirin Combinations against Rift Valley Fever Virus Infection in Mice," Antimicrobial Agents and Chemotherapy, American Society for Microbiology, July 1987, Vol. 31(7) p. 986-990.				
		LAKE et al. Involvement of protein kinase C in macrophages activation by poly (C). American Journal of Physiology (1994) vol. 266(1) pp. C134-42.				

Examiner Signature	/Emily Le/	Date 01/28/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO:

Receipt date: 03/30/2007

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Unde	a die Paperwork Reduction Accor	1000,	no persons are red	ulled to respond to a collection of linio	mation unless it contains a valid OMB control number.	
Substitute	Substitute for form 1449A/PTO			Cor	Complete if Known	
				Application Number	10/551,847	
	INFORMATION DISCLOSURE			Filing Date	June 23, 2006	
STATEMENT BY APPLICANT			ANT	First Named Inventor	HAIXIANG, LIN	
				Art Unit	Unassigned	
	(use as many sheets as necessary)			Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	NBMP-001	

	NON PATENT LITERA	TURE DOCUMENTS	
	LEVY et al. "Immune Modulating Effects of Poly p.33-41.	ICLC," Annals New York Aca	ademy of Sciences, 1980,
	LIN et al. A new immunostimulatory complex (effects. Archives of Virology (1993) col. 131: pp.		s: antiviral and adjuvant
_			
_		1 131 F A	
+			
+			
Examiner Signature	/Emily Le/	Date Considered	01/28/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering. preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,